In addition to the detailed investigation of PD-1/PDL-1 and CTLA4 in tumor immunotherapies, recent studies have also focused on new IC targets, including LAG-3, TIM-3 and TIGIT, which form the second tier of IC molecules with more distinct and specific roles in immune response regulation [4]. The gene discussed is HAVCR2; the disease is neoplasm.